Recombinant coxsackievirus B3

重组柯萨奇病毒B3

Report date: 2023/02/26 21:49:37

Base Information

Drug NameRecombinant coxsackievirus B3
Drug Alias NameCVB-3重组柯萨奇病毒B3注射液CVB3
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionApoptosis stimulantsComplement decay-accelerating factor modulators
TargetsComplement decay-accelerating factor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Boweid Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Boweid Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A